Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NBX-300
- Development stage
- Preclinical
- Lead developer
- Neurala Biosciences
- Modality
- Small Molecules
01
Overview
**NBX-300** is a preclinical, sub-perceptual small-molecule DMT-harmala neuromedicine being developed by Neurala Biosciences for affective disorders. It is part of Neurala's proprietary DMT-harmala platform, which is intended to create differentiated neuropsychiatric medicines through compound selection, structural refinement, dosing, formulation, and delivery-route optimization. The precise chemical composition, molecular targets, pharmacologic mechanism, dosage form, route of administration, and manufacturing supplier for NBX-300 have not been publicly disclosed. ([neurala.co](https://www.neurala.co/science))
Beyond the preview
Go deeper on NBX-300.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NBX-300.